UiPath (NYSE:PATH) has launched agentic AI automation tools tailored for healthcare providers and payers. The company is ...
UiPath’s blended fair value estimate has been trimmed from US$16.19 to US$15.93, a move that sits alongside bullish analyst price targets up to US$18 and recent target cuts from more cautious voices.
Celonis evangelist Rudy Kuhn argues that without process intelligence, AI agents are flying blind - and that composability, not another three-year transformation program, is the real key to enterprise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results